MCC
57 programs · 55 companies
Programs
57
Companies
55
Trials
44
MOAs
36
SHP2iIL-13iPI3KiBTKiCDK2iALKiTROP-2 ADCCl18.2HER2PCSK9i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | NDA/BLA | GLP-1R | ||
| BMY-4586 | Preclinical | KRASG12C | ||
| Rimatenlimab | Phase 2/3 | SGLT2 | ||
| Lisorapivir | Preclinical | WRN | ||
| MRN-7409 | NDA/BLA | SHP2 | ||
| Talatenlimab | Phase 1/2 | KIF18A | ||
| Zoriosocimab | Approved | C5 | ||
| ELV-1411 | NDA/BLA | HER2 | ||
| Lisosotorasib | Phase 2/3 | CDK4/6 | ||
| Nirasertib | Phase 2/3 | CD19 | ||
| EQR-8061 | Phase 1 | BCL-2 | ||
| FOR-4809 | Phase 1 | PLK4 | ||
| CON-4833 | Phase 2/3 | CD20 | ||
| BTA-3746 | Phase 2 | C5 | ||
| CHI-3542 | Phase 2 | CD19 | ||
| CON-372 | Approved | MALT1 | ||
| BIO-708 | Phase 2/3 | Menin | ||
| Mirinaritide | Phase 2/3 | Cl18.2 | ||
| Ivovorutinib | NDA/BLA | CD38 | ||
| Polatinib | Phase 2 | Tau | ||
| Talatinib | Approved | WEE1 | ||
| ENC-6986 | Approved | PLK4 | ||
| Zoricilimab | Phase 2 | SOS1 | ||
| Sotocapivasertib | Approved | TIGIT | ||
| 003-4903 | Phase 3 | BCMA | ||
| Zoriosocimab | Phase 3 | MET | ||
| Talazanubrutinib | Phase 1/2 | MDM2 | ||
| VEC-8813 | Phase 3 | JAK2 | ||
| AUT-9774 | Phase 2/3 | BTK | ||
| VAL-4454 | Preclinical | Aβ | ||
| AVR-5957 | NDA/BLA | EZH2 | ||
| Lisosotorasib | Phase 3 | GPRC5D | ||
| FYB-2633 | Phase 1 | MALT1 | ||
| Tixarelsin | Phase 2/3 | CFTR | ||
| SYN-2281 | Phase 1/2 | CD19 | ||
| Nidaglumide | Approved | C5 | ||
| Tezerelsin | Phase 1/2 | SOS1 | ||
| Liracapivasertib | Phase 1 | GIP-R | ||
| HYP-6536 | Preclinical | MET | ||
| Datofotisoran | Phase 1/2 | PARP | ||
| SIA-643 | Phase 1 | BCL-2 | ||
| APN-6857 | Phase 2 | GPRC5D | ||
| APN-2677 | NDA/BLA | FcRn | ||
| PRI-IIT-139 | Preclinical | FcRn | ||
| NAT-IIT-995 | Approved | TNFα | ||
| KIN-IIT-683 | Phase 2 | TYK2 | ||
| Elrazanubrutinib | NDA/BLA | APOC3 | ||
| Doxafotisoran | Phase 1 | GIP-R | ||
| Liranesiran | Phase 3 | Tau | ||
| BRK-679 | Approved | PRMT5 | ||
| Datozanubrutinib | NDA/BLA | PRMT5 | ||
| EUP-1431 | Phase 2 | PRMT5 | ||
| VEE-3535 | NDA/BLA | TIM-3 | ||
| Polanaritide | Phase 1/2 | C5 | ||
| Kemalucimab | Phase 2/3 | CD47 | ||
| 115-4305 | NDA/BLA | Cl18.2 | ||
| 453-4974 | NDA/BLA | PLK4 |
Trials (44)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06111957 | PFE-2191 | NDA/BLA | Not yet recr... |
| NCT03331938 | Rimatenlimab | Phase 2/3 | Not yet recr... |
| NCT05465371 | Lisorapivir | Preclinical | Not yet recr... |
| NCT07119774 | Lisorapivir | Preclinical | Completed |
| NCT04049680 | Talatenlimab | Phase 1/2 | Active |
| NCT05796936 | Talatenlimab | Phase 1/2 | Not yet recr... |
| NCT04226228 | Nirasertib | Phase 2/3 | Terminated |
| NCT06754103 | Nirasertib | Phase 2/3 | Completed |
| NCT04223508 | EQR-8061 | Phase 1 | Not yet recr... |
| NCT03301958 | FOR-4809 | Phase 1 | Terminated |
| NCT05359294 | FOR-4809 | Phase 1 | Completed |
| NCT04972664 | BTA-3746 | Phase 2 | Recruiting |
| NCT08810682 | CHI-3542 | Phase 2 | Completed |
| NCT06468551 | BIO-708 | Phase 2/3 | Not yet recr... |
| NCT07056863 | Mirinaritide | Phase 2/3 | Terminated |
| NCT07581152 | Ivovorutinib | NDA/BLA | Not yet recr... |
| NCT04585461 | Ivovorutinib | NDA/BLA | Completed |
| NCT04500954 | Talatinib | Approved | Terminated |
| NCT05390098 | ENC-6986 | Approved | Completed |
| NCT05201080 | ENC-6986 | Approved | Active |